Skip to main content
AARD
NASDAQ Life Sciences

Aardvark Books Q1 2027 FDA Meeting to Map ARD-101 Restart After Hold Lifted

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$1.52
Mkt Cap
$33.265M
52W Low
$0.93
52W High
$16.6
52W Position info
63% above low
Off High info
91% below high
Rel. Volume info
0.4× avg
Market data snapshot near publication time

AARD sits 63% above its 52-week low of $0.93 on light trading volume (0.4× avg).

Summary

Aardvark's Q3 release confirms the $19.2M quarterly loss and $60.3M cash balance already reported, and adds the key new item: an FDA meeting in Q1 2027 to agree on the ARD-101 PWS development plan, with clinical work expected to restart in 2027.


Key Events · Earnings and Guidance · AARD

  • Q1 2027 FDA Meeting Scheduled

    Aardvark has requested and been scheduled a meeting with the FDA for the first quarter of 2027 to discuss its proposed ARD-101 clinical development plan in PWS. The company expects to resume PWS clinical activities in 2027, subject to alignment with the agency.

  • Q3 Loss and Cash Balance

    Net loss was $19.2M ($0.88 per share) for Q3 2026 versus $16.3M a year earlier. Cash, cash equivalents and short-term investments totaled $60.3M at September 30, 2026, down from $73.9M at June 30, 2026.

  • Runway Through 2027, Phase 3 Funding Gap

    Management says existing cash funds projected operations through 2027, but the release separately flags the risk of the ability to raise sufficient capital to fund a planned Phase 3 program — with a $150M at-the-market facility established in March 2026 available as a dilution lever.

  • R&D Spend Rises on Cardiac Safety Work

    R&D expense was $15.7M in Q3 2026 versus $13.7M in Q3 2025, a $1.9M increase driven by the FDA-required cardiac safety study of ARD-101 and higher personnel costs, partly offset by lower trial costs after the HERO and OLE terminations.


Analysis · AARD · Life Sciences

The Q3 numbers were already out via the same-day 10-Q and press coverage: a $19.2M net loss and $60.3M in cash. What is new is the calendar. Management now has a first-quarter 2027 FDA meeting booked to argue for its proposed ARD-101 development plan in Prader-Willi syndrome, and it expects clinical activity to resume in 2027 only if the agency agrees. That converts an open-ended post-hold situation into a dated decision point. It also frames the cash question: $60.3M is enough to run the current cost base through 2027, but the press release itself flags the risk that a full Phase 3 program may require more capital — against an existing $150M at-the-market facility established in March 2026. Until the FDA feedback lands, the stock trades on a binary regulatory readout roughly a quarter away.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, AARD was trading at $1.52 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $33.3M. The 52-week trading range was $0.93 to $16.60. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

AARD - Latest Insights

AARD
Nov 13, 2026, 7:47 AM EST
Source: Reuters
Importance Score:
7
Price at Filing: $1.52
Real-time Price: $1.52 info
Change: -$0.0003 (-0.02%) info
Market Cap: $33.265M info
AARD
Nov 12, 2026, 7:56 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $1.51
Real-time Price: $1.52 info
Change: +$0.0097 (+0.64%) info
Market Cap: $33.265M info
AARD
Oct 23, 2026, 8:38 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.09
Real-time Price: $1.52 info
Change: -$1.57 (-51%) info
Market Cap: $33.265M info
AARD
Oct 22, 2026, 4:05 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $3.95
Real-time Price: $1.52 info
Change: -$2.43 (-62%) info
Market Cap: $33.265M info
AARD
Aug 11, 2026, 5:09 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $7.33
Real-time Price: $1.52 info
Change: -$5.81 (-79%) info
Market Cap: $33.265M info